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Oral Presentations S181CB, and 3-4/6 unrelated CB. Tacrolimus and mycophenolate mofe-
til were used as GVHD prophylaxis (Bhatia/Cairo et al, BBMT
2009) and phenytoin or levetiracetam as seizure prophylaxis for
180 days post-SCT. Organ function testing (MRI/MRA, ECHO,
and PFT) was done pre-SCT and 1 and 2 yrs post-SCT in evaluable
patients. The median follow up is 2.3 yrs (0.6-6.1 yrs). The OS, EFS,
and median 1 and 2 year donor chimerism (WB/CD71) are 83%,
78%, 93/90% and 94/95%, respectively (Bhatia/Cairo et al, ASH
2010). Of the 15 evaluable patients, 9 and 7 patients had a repeat
MRI at 1 and 2 yrs, respectively. All had stable or improved MRI
with the exception of 1 pt who had an embolic CVA on MRI 7
months post-SCTwhich resolved one month later. Sixteen of 18 pa-
tients had pre-SCT ECHO and of those, 3 were noted to have mild
to moderate tricuspid regurgitation (TR). Of those three patients,
two were evaluable at 1 and 2 yrs post-SCT, and were noted to
have improvement in degree of TR, which was noted to be trivial
in one, and trivial to mild in the other. Of evaluable patients at 1
(n 5 9) and 2 yrs (n 5 7) post-SCT, all were noted to have stable
or improving TR with no patient demonstrating evidence of pulmo-
nary hypertension. All patients greater than 8 yrs of age underwent
PFTs. 11 patients had pre-SCT PFTs with 2/11 having restrictive
disease and 1/11 having obstructive disease. Of the nine patients
who were evaluable for comparison before and after SCT, the
mean predicted FVC changed from 90 6 23% to 93.5 6 16% and
the mean predicted FEV1 changed from 876 29% to 906 18% af-
ter transplantation. In conclusion, RTC SCT effectively promoted
stable donor engraftment in SCD pts and was associated with stable
or improved organ stability function at 2 years post-SCT.
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NONMYELOABLATIVE CONDITIONING FOLLOWED BY ALLOGENEIC
MARROW GRAFTS FOR TREATMENT OF PRIMARY IMMUNE DEFICIENCY
DISORDERS: PRELIMINARY RESULTS OF A PHASE II STUDY
Burroughs, L.1,2, Torgerson, T.2, Storer, B.1,3, Leisenring, W.1,3,
Nemecek, E.4, Frangoul, H.5, Walters, M.C.6, Scharenberg, A.2,
Rawlings, D.J.2, Skoda-Smith, S.2, Ochs, H.2, Storb, R.1,2,Table 1. Pre-transplant risk factors and survival among 23 patients
geneic marrow grafts for high-risk PIDD
Patient # Diagnosis Age (yr)/Gender
1 SCID 1.4/F Parainfluenza, Rhinovirus, P
2 X-SCID 0.5/M CMV reactivation
3 X-SCID 0.8/M Adenovirus, PCP, FTT
4 SCID 1.9/M Disseminated CMV disease
5 SCID 1.2/F Disseminated CMV disease
6 SCID 0.9/M PCP, Influenza B, Rhinoviru
7 SCID 1.0/F Disseminated adenovirus w
8 SCID 0.4/M Parvovirus, FTT
9 Complete DiGeorge 0.4/M Seizures, FTT
10 CID 9.8/F CMV reactivation, chronic
hyperammonemia and e
tubular acidosis, polyarti
FTT
11 CID 0.7/F Enterovirus pneumonia (m
12 CID 2.9/M Bronchitis, recurrent pneu
13 CVID 24.7/F CMV reactivation, Candida
disease with portal HTN
14 CGD 26.5/M Pulmonary Scopulariopsis,
15 CGD 10.7/M Invasive pulmonary Asperg
16 IPEX 16.9/M EBV LPD of the lungs & gu
17 CHH 2.9/F Enterovirus, Norovirus, Hi
FTT
18 CHH 8.7/F CMV reactivation, chronic
19 HLH 2.7/M Pneumonia, h/o multi-syste
HCT
20 Congenital Neutropenia 3.5/M Primary EBV infection
21 HLH 0.6/F HLH
22 ADA-SCID 0.7/M Recurrent viral pneumonia
23 CD40LD 11.3/M CD40LD, s/p colectomy du
CD40LD5 CD40 ligand deficiency; CGD5chronic granulomatous disease; CH
variable immunodeficiency; EBV-LPD5Epstein-Barr virus lymphoproliferative d
tus; HLH5 hemophagocytic lymphohistiocytosis; h/o5history of; HTN5hyper
X–linked; PCP5pneumocystis carnii pneumonia; (S)CID5(severe) combined i
tosystemic shunt, yr5year. Patients 21, 22 and 23 received Alemtuzumab as p
> Alive; †Dead; #NumberWoolfrey, A.1,2 1Fred Hutchinson Cancer Research Center; 2University
of Washington School of Medicine; 3University of Washington School of
Public Health; 4Oregon Health & Sciences University; 5Vanderbilt
University; 6Children’s Hospital & Research Ctr, Oakland
Myeloablative conditioning regimens may cause life threatening
transplant related toxicities in patients with Primary Immune Defi-
ciency Disorders (PIDD), particularly in patients with co-morbid
conditions. Previously we reported the outcomes of a phase I study
using nonmyeloablative conditioning in 14 high-risk patients with
PIDD and observed 3-year survival and transplant related mortality
(TRM) of 62% and 23%, respectively. Although encouraging, the
incidence of chronic GVHDwas 47% at 1 year, which is an undesir-
able outcome for patients with nonmalignant diseases. We reasoned
that the incidence of GVHD might be reduced by replacing PBSC
with marrow; however, our previous experience showed marrow to
be associatedwith a higher risk of graft rejection.Therefore our stan-
dard nonmyeloablative regimen of 90 mg/m2 fludarabine and 2 Gy
total body irradiation (TBI) was slightly intensified to include either
Alemtuzumab, or, if Alemtuzumab was contraindicated, an
additional 2 Gy TBI.
Twenty-three patients with PIDD and significant underlying seri-
ous infections and/or organ dysfunction (table 1) were given HLA-
matched related (n5 10) or unrelated (n5 13) marrow grafts follow-
ing nonmyeloablative conditioning modified with either Alemtuzu-
mab (n 5 3) or 4 Gy TBI (n 5 20). All patients received
mycophenolate mofetil and cyclosporine for postgrafting immuno-
suppression. Of the 20 patients evaluable, 18 had mixed (6-49%, n
5 1; 50-94%; n 5 10) or full (. 95%; n 5 7) donor CD31 T-cell
chimerism. Two patients had graft rejection and survive disease-
free following 2nd successful transplantation. The 2-year cumulative
incidence of chronic GVHD was 22%. With a median follow-up of
26.8 months, the 2-year survival was 76% and the day 200 and 2-year
TRM were 14% and 24%, respectively. Four patients died of pre-
existing infections and/or organ dysfunction and one patient died
of GVHD. Six patients were not evaluable for disease response due
to short follow-up (n 5 1), 2nd HCT (n 5 2), or early death (n 5who received nonmyeloablative conditioning followed by allo-
Pre-transplant Risk Factors Survival (months)
CP, FTT >48.7
>45.1
>36.0
with pneumonitis, myocarditis, nephritis, and hepatitis, FTT >27.8
with pneumonitis, adenovirus pneumonitis, PCP, FTT †Day +1
s, FTT †7.5
ith hepatitis, FTT †Day +15
>Day +4
>23.7
lung disease, h/o fulminant hepatic failure with
ncephalopathy, h/o acute renal failure with persistent renal
cular arthritis, Moraxella catarrhalis sinusitis and pneumonia,
>27.6
echanical ventilation dependent before and at time of HCT) †1.4
monia >2.3
pneumonia, lymphocytic interstitial pneumonitis, liver
of unknown etiology s/p TIPS procedure, IDDM
>11.1
FTT >26.9
illosis, Protein losing enteropathy >15.0
t, chronic interstitial lung disease, IDDM >26.0
rschsprung’s disease s/p total colectomy, TPN dependent, >4.3
lung disease, hemolytic anemia >4.3
m organ failure - shock, renal failure – dialysis dependent at †7.4
>45.1
>43.4
s, FTT >42.0
e to pre HCT dysplasia throughout colon >35.7
H5cartilage hair hypoplasia; CMV5cytomegalovirus; CVID5common
isease; FTT5failure to thrive; IDDM5insulin dependent diabetes melli-
tension; IPEX5immune dysregulation-polyendocrinopathy-enteropathy-
mmune deficiency; s/p5status post; TIPS5transjugular intrahepatic por-
art of the conditioning regimen.
S182 Oral Presentations3). Fifteen patients had improvement in, or correction of, their un-
derlying PIDD. Although these results are preliminary, our early ex-
perience suggests that outcomes can be improved in high-risk
patients with PIDD by using a modified nonmyeloablative
conditioning regimen and by selecting marrow as the source of he-
matopoietic cells. We observed stable donor engraftment in most
cases, an acceptable TRM, a low incidence of chronic GVHD, and
correction of underlying disease processes.76
MEGADOSES OF HAPLOCOMPATIBLE RELATED CD341 CELLS UTILIZING
CLINIMACS-BASED SELECTIONWITH A FIXED CD31 DOSE IN PEDIATRIC
PATIENTS IS SAFE AND EFFECTIVE
Dvorak, C.C.1, Gilman, A.L.2, Horn, B.1, Oon, C.-Y.1, Cowan, M.J.1
1University of California San Francisco Benioff Children’s Hospital, San
Francisco, CA; 2Levine Children’s Hospital, Carolinas Medical Center,
Charlotte, NC
Many patients lack an HLA-matched donor. We evaluated
whether the use of a fixed dose of CD31 cells with megadoses of
CD341 cells from Haplocompatible related donors (HRDs) would
be associated with good outcomes in children.
From 2002 to 2010, we performed a prospective Phase II trial uti-
lizing the CliniMACs (Miltenyi Biotec, Bisley, UK) system to per-
form CD341 cell selection of PBSC from HRDs in 21 pediatric
patients (median age 6.4 yrs, range 1.4-20.5 yrs). 15 patients had a he-
matologicmalignancy (AML/MDS, n5 9; ALL, n5 4; CML, n5 1;
JMML, n 1), 6 patients had a non-malignant condition (Bone Mar-
row Failure, n 5 3; HLH, n 3). Conditioning was TBI 1200 cGy
(200 cGy bid on Days -9 to -7), Thiotepa (5 mg/kg/dose bid on
Day -6), Fludarabine (40mg/m2/dose onDays -6 to -2), andThymo-
globulin (0.5 mg/kg on Day -5, 1 mg/kg on Days -4 to -2). Patients
received a median of 20  106/kg (range: 11-33  106/kg) CD341
cells with 3  104/kg CD31 cells/kg. Events were: graft failure, re-
lapse, and TRM. Statistics were performed using SPSS 16.0. EFS
was estimated using the Kaplan-Meier method.
Engraftment occurred in all but 2 patients (90%; 95% CI, 70-
99%), both with AML/MDS. Relapse occurred in 3 of 15 patients
(20%; 95% CI, 6-46%) at a median of 3.7 months (range: 1.3-12.4
months) post-HCT. All 5 patients eventually expired, despite 2nd
HRD HCT for 4 patients. One or more planned DLI (3  104
CD31 cells/kg) were administered to 11 patients to enhance immu-
nologic recovery. Grade I-II aGVHD was seen in 9 of 19 evaluable
patients (47%; 95% CI, 27-68%). There was no Grade III-IV
aGVHD. cGVHD was seen in 6 of 17 evaluable patients (35%;
95%CI, 17-59%). Infections (Sepsis &Mucor) resulted in the death
of 2 patients (10%; 95% CI, 1-30%) at 11 & 22 months post-HCT;
both were being treated for cGVHD. For all patients, the est. 2-year
EFS was 61% (95% CI, 49-73%). Patients with non-malignant dis-
eases had an est. 2-year EFS of 100% (95% CI, 56-100%). Patients
with malignancy in remission (n 9) had an est. 2-year EFS of 64%
(95% CI, 47-80%), while those not in remission (n 6) had an est.
2-year EFS of only 22% (95% CI, 3-41%). Median follow-up of
survivors was 34 months (range: 3-103 months).
Megadose CD341 cells with a fixed CD31 cell dose from HRDs
resulted in outcomes similar to those seen with other alternative-
donor stem cell sources. For pediatric patients with non-malignant
diseases or those transplanted in remission, outcomes were excellent.77
LUNG BIOPSY IN CHILDREN POST HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Craig-Barnes, H.A., Schechter, T., Doyle, J., Gassas, A. The Hospital for
Sick Children, Toronto, ON, Canada
Introduction: Pulmonary complications are common post hemato-
poietic stem cell transplantation (HSCT). Lung biopsies are invasive
procedures and their utility in the management of care of these pa-
tients is uncertain. This study aims to determine whether the diagno-
ses provided by lung biopsies change the management of care in
a pediatric HSCT patient population.Methods: We retrospectively reviewed charts from patients who
had a lung biopsy after a HSCT at The Hospital for Sick Children
in Toronto, Canada. The results of the lung biopsies were correlated
with the clinical management pre- and post-biopsy.
Results: From January 2000 to June 2010, 918 patients received
HSCT (allogeneic 476, autologus 442). A total of 59 biopsies
were performed in 48 patients (ages 6 months -17 years). Of the
48 patients, 32 patients received allo HSCT (20- malignant and
12- non-malignant) and 16 patients received auto HSCT. Biopsies
were open lung biopsies via a thoracotomy (38), thoracoscopic (9),
and percutaneous needle biopsy (12). The median time from
HSCT to biopsy was 3 months (range 7 days – 50 months). The
primary diagnosis from the biopsies was lung damage (vasculop-
athy, type II pneumocyte hyperplasia) attributed to drug or radia-
tion toxicity in 15 patients (25%). This was followed by recurrence
or metastasis of the primary malignant disease in 13 (22%), diffuse
alveolar damage in 10 (17%), interstitial inflammation in 7 (12%),
confirmed infection in 5 (8%), interstitial pneumonitis in 3 (5%),
BO(OP) in 2 (3%), ARDS in 1 (2%), pneumonia without an organ-
ism in 1(2%), pulmonary alveolar protienosis in 1 (2%) and nega-
tive findings in 1 patient (2%). Apart from the patients with
recurrent malignant disease results on biopsy, there were no major
changes in patients’ management of care after the lung biopsy.
Thirty-three patients died after the lung biopsy (68.75%) at a me-
dian of 1 month (range 1 day – 55 months). Cause of death in these
patients was primarily respiratory failure in 16 (48%) followed by
progression of malignant disease in 12 (36%), cardiac arrest in 3
(9%), infection in 1 (3%), GvHD 1 (3%). Death was most common
in patients who had open lung biopsies; 66% of open lung biopsies
were followed by death.
Conclusions: A decision to perform a lung biopsy in children post
HSCT is an indicator for poor prognosis. Apart from confirming
malignant progression or rare infectious microorganisms, results
from lung biopsies did not alter their management significantly.78
FAVORABLE PRELIMINARY RESULTS USING TLI/ATG-BASED PRE-TRANS-
PLANT CONDITIONING FOR MATCHED UNRELATED DONOR ALLOGE-
NEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PEDIATRIC SEVERE
APLASTIC ANEMIA
Pillai, A.1, Hartford, C.1,Wang, C.2, Pei, D.2, Yang, J.2, Srinivasan, A.1,
Triplett, B.1, Dallas, M.1, Leung,W.1 1St. Jude Children’s Research Hos-
pital, Memphis, TN; 2St. Jude Children’s Research Hospital, Memphis,
TN
Current treatment algorithms for pediatric severe aplastic anemia
(SAA) entail up-frontmatched sibling donor (MSD)HCT, or immu-
nosuppressive therapy for those withoutMSD. To assess whether an
immunoablative tolerance-induction regimen for unrelated (MUD)
HCT could be applied to extend up-front application of HCT in
SAA, we retrospectively reviewed our single-institution HCT
experience from 1999-2009 (minimum 1-year follow-up) for SAA
patients using unmanipulated bone marrow grafts from high-resolu-
tion 10/10 HLA-matched donors. Conditioning (cumulative dose)
was cyclophosphamide 200 mg/kg (CTX) 1 rabbit ATG 10 mg/kg
(rATG) for MSD (n 5 9) versus total lymphoid irradiation (TLI,
800 cGy) 1 CTX/rATG for MUD HCT (n 5 5). Immunoprophy-
laxis was cyclosporine A (CSA) and short-course methotrexate for all
patients. Ten of 14 patients were Caucasian, 7 were female, median
age at time of HCT was 14.7 years (range, 4.6 - 19.3), and median
follow-up 3.0 years (range, 1.1 - 10.3). All patients were chronically
platelet and erythrocyte transfusion-dependent at HCT. Mean
CD341 cell dose (MSD: 6.2 64.2  106/kg; MUD: 3.9 62.4 
106/kg) and mean CD31 cell dose (MSD: 28.3 616.2  106/kg;
MUD: 29.4 615.8  106/kg) were not significantly different be-
tween groups. Themajor outcomemeasures were event-free survival
(EFS), engraftment rate, time to engraftment, and cumulative inci-
dence of GVHD within 1 year (CIN of GVHD) for MSD and
MUD cohorts. The EFS and stable engraftment rates were 100%
for MSD and MUD, and time to engraftment of ANC and platelets
was not significantly different between MSD and MUD (p . 0.25).
CIN of acute GVHD was: MSD, Grade I-II: 11%, Grade III-IV:
